Comparison Overview

Hikma Pharmaceuticals

VS

Cipla

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB
Last Update: 2026-04-03
View Profile
Between 750 and 799
http://www.hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,252
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Cipla

Lower Parel, Ganpatrao Kadam Marg,, Mumbai, Maharashtra, IN, 400013
Last Update: 2026-04-01
Between 750 and 799
http://www.cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 50,326
Subsidiaries: 7
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Hikma Pharmaceuticals
100%
Compliance Rate
0/4 Standards Verified
Cipla
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Cipla in 2026.

Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Incident History — Cipla (X = Date, Y = Severity)

Cipla cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
Incidents

No Incident

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
Incidents

No Incident

FAQ

Cipla company demonstrates a stronger AI Cybersecurity Score compared to Hikma Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Cipla company has disclosed a higher number of cyber incidents compared to Hikma Pharmaceuticals company.

In the current year, Cipla company and Hikma Pharmaceuticals company have not reported any cyber incidents.

Neither Cipla company nor Hikma Pharmaceuticals company has reported experiencing a ransomware attack publicly.

Neither Cipla company nor Hikma Pharmaceuticals company has reported experiencing a data breach publicly.

Neither Cipla company nor Hikma Pharmaceuticals company has reported experiencing targeted cyberattacks publicly.

Neither Hikma Pharmaceuticals company nor Cipla company has reported experiencing or disclosing vulnerabilities publicly.

Neither Hikma Pharmaceuticals nor Cipla holds any compliance certifications.

Neither company holds any compliance certifications.

Cipla company has more subsidiaries worldwide compared to Hikma Pharmaceuticals company.

Cipla company employs more people globally than Hikma Pharmaceuticals company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Hikma Pharmaceuticals nor Cipla holds SOC 2 Type 1 certification.

Neither Hikma Pharmaceuticals nor Cipla holds SOC 2 Type 2 certification.

Neither Hikma Pharmaceuticals nor Cipla holds ISO 27001 certification.

Neither Hikma Pharmaceuticals nor Cipla holds PCI DSS certification.

Neither Hikma Pharmaceuticals nor Cipla holds HIPAA certification.

Neither Hikma Pharmaceuticals nor Cipla holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

nimiq/core-rs-albatross is a Rust implementation of the Nimiq Proof-of-Stake protocol based on the Albatross consensus algorithm. Prior to version 1.3.0, two peer-facing consensus request handlers assume that the history index is always available and call blockchain.history_store.history_index().unwrap() directly. That assumption is false by construction. HistoryStoreProxy::history_index() explicitly returns None for the valid HistoryStoreProxy::WithoutIndex state. when a full node is syncing or otherwise running without the history index, a remote peer can send RequestTransactionsProof or RequestTransactionReceiptsByAddress and trigger an Option::unwrap() panic on the request path. This issue has been patched in version 1.3.0.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 5.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

PraisonAI is a multi-agent teams system. Prior to version 1.5.95, FileTools.download_file() in praisonaiagents validates the destination path but performs no validation on the url parameter, passing it directly to httpx.stream() with follow_redirects=True. An attacker who controls the URL can reach any host accessible from the server including cloud metadata services and internal network services. This issue has been patched in version 1.5.95.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 8.6
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N
References
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, OAuthManager.validate_token() returns True for any token not found in its internal store, which is empty by default. Any HTTP request to the MCP server with an arbitrary Bearer token is treated as authenticated, granting full access to all registered tools and agent capabilities. This issue has been patched in version 4.5.97.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
References
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, the PraisonAI Gateway server accepts WebSocket connections at /ws and serves agent topology at /info with no authentication. Any network client can connect, enumerate registered agents, and send arbitrary messages to agents and their tool sets. This issue has been patched in version 4.5.97.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
References
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.90, MCPToolIndex.search_tools() compiles a caller-supplied string directly as a Python regular expression with no validation, sanitization, or timeout. A crafted regex causes catastrophic backtracking in the re engine, blocking the Python thread for hundreds of seconds and causing a complete service outage. This issue has been patched in version 4.5.90.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
References